TABLE 3.
Characteristics of fluconazole-resistant isolates from patients with candidemia
| Isolate no. | Species | Fluconazole MIC (mg/liter) | ERG3-ERG 11 sequence | Ward | Date of isolation (day/mo/yr) | Genotype |
|---|---|---|---|---|---|---|
| 1 | C. albicansa | >64 | V351A-D116E/D E266D V488I/V | Digestive | 23/08/2010 | CA-170 |
| 2 | C. albicansa | 8 | V351A-A114S Y257H G464S/G | Neonatology ICU | 27/07/2011 | CA-276 |
| 3 | C. albicansa | >64 | T291I V351A-wild type | Internal medicine | 13/11/2019 | CA-313 |
| 4 | C. albicansa | >64 | V351A-wild type | Neurosurgery | 15/03/2015 | CA-413 |
| 5 | C. glabrataa | 64 | NDd | Oncology | 25/05/2018 | CG-01 |
| 6 | C. glabrataa | >64 | ND | Oncology | 08/11/2011 | CG-06 |
| 7 | C. glabratab | 64 | ND | Urology | 22/12/2008 | CG-09 |
| 8 | C. glabrataa | >64 | ND | ICU | 09/10/2007 | CG-13 |
| 9 | C. glabratab | 32 | ND | ICU | 12/01/2014 | CG-15 |
| 10 | C. glabratab | 64 | ND | Digestive | 13/08/2015 | CG-15 |
| 11 | C. glabrataa | 64 | ND | Emergency | 21/10/2007 | CG-23 |
| 12 | C. glabratab | 32 | ND | ICU | 26/01/2010 | CG-24 |
| 13 | C. glabrataa | >64 | ND | Surgery | 11/09/2015 | CG-24 |
| 14 | C. glabratac | 64 | ND | Surgery | 12/07/2019 | CG-27 |
| 15 | C. krusei | 32 | ND | Geriatrics | 02/01/2007 | ND |
| 16 | C. krusei | 16 | ND | Oncology | 27/11/2007 | ND |
| 17 | C. krusei | 32 | ND | ICU | 28/09/2010 | ND |
| 18 | C. krusei | 64 | ND | ICU | 27/12/2010 | ND |
| 19 | C. krusei | 32 | ND | ICU | 08/03/2011 | ND |
| 20 | C. krusei | 32 | ND | Oncology | 02/01/2012 | ND |
| 21 | C. krusei | 32 | ND | Digestive | 05/03/2012 | ND |
| 22 | C. krusei | 64 | ND | Nephrology | 29/05/2012 | ND |
| 23 | C. krusei | 64 | ND | Infectious diseases | 05/04/2013 | ND |
| 24 | C. krusei | 16 | ND | Digestive | 14/11/2014 | ND |
| 25 | C. krusei | 64 | ND | Onco/Hematoe | 24/11/2014 | ND |
| 26 | C. krusei | 32 | ND | Onco/Hemato | 24/04/2015 | ND |
| 27 | C. krusei | 16 | ND | Onco/Hemato | 16/07/2015 | ND |
| 28 | C. krusei | 32 | ND | ICU | 06/04/2016 | ND |
| 29 | C. krusei | 16 | ND | Oncology | 15/06/2016 | ND |
| 30 | C. krusei | 16 | ND | Onco/Hemato | 29/11/2016 | ND |
| 31 | C. krusei | 16 | ND | Oncology | 07/03/2017 | ND |
| 32 | C. krusei | 32 | ND | Internal medicine | 22/09/2018 | ND |
| 33 | C. krusei | 64 | ND | Onco/Hemato | 29/09/2018 | ND |
| 34 | C. krusei | 64 | ND | Intensive medicine | 17/03/2019 | ND |
| 35 | C. krusei | 64 | ND | Intensive medicine | 09/04/2019 | ND |
| 36 | C. guilliermondii | 16 | ND | Surgery | 10/10/2008 | ND |
| 37 | C. guilliermondii | 16 | ND | Digestive | 23/04/2013 | ND |
| 38 | C. guilliermondii | >64 | ND | Internal medicine | 31/01/2018 | ND |
| 39 | C. lusitaniae | 16 | ND | Onco/Hemato | 30/05/2010 | ND |
| 40 | C. lusitaniae | 32 | ND | Neurosurgery | 28/12/2014 | ND |
| 41 | C. inconspicua | 8 | ND | Traumatology | 22/01/2015 | ND |
a
Pan-azole-resistant isolate.
b
Cross-resistance among fluconazole and isavuconazole.
c
Cross-resistance among fluconazole, posaconazole, and isavuconazole.
d
ND, not done.
e
Onco/Hemato, Oncology and Hematology.